Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
Despite the hypothesized role of SLFN11 as a predictive biomarker for chemotherapy efficacy, no significant association was found between SLFN11 expression and clinical outcomes in PDAC. Further studies with larger cohorts and more detailed staging are needed to clarify the potential utility of SLFN11 as a therapeutic biomarker in PDAC.
Authors
- Naoya Sakamoto (ORCID: https://orcid.org/0000-0001-6273-0189)
- Kazuaki Harada (ORCID: https://orcid.org/0000-0001-9577-1884)
- Kanako C. Hatanaka (ORCID: https://orcid.org/0009-0008-9596-9661)
- Takeaki Nakamura
- Y. Kawamoto
- Yoshito Komatsu (ORCID: https://orcid.org/0000-0002-1570-6802)
- Yutaka Hatanaka (ORCID: https://orcid.org/0000-0003-3128-1477)
- Satoshi Yuki (ORCID: https://orcid.org/0000-0002-2039-3062)
- Koichi Ishida
- Shiho Kaneko
Institutions
- Hokkaido University Hospital (JP)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1007/s00432-025-06216-8
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09